Methods and compositions for the treatment of cirrhosis and liver fibrosis
AssigneeProyecto De Biomedicina Cima, S.L.
InventorsMaria Purificaion Fortes Alonso, Jesús Maria Prieto Valtueña, Luciano Matías Sobrevals, Harald Petry, Eric Jacobus Hubertus Timmermans
Life of this patent
Estimating the term…
Abstract
The invention provides a method for the treatment of cirrhosis and liver fibrosis by the use or viral vectors containing the gene encoding IGF-I. The invention discloses both parvoviral vectors and SV40-based vectors as well uses thereof for the treatment of cirrhosis and gene therapy and methods for the preparation of said viral vectors.
Claims22
(canceled)
2-34. (canceled)
A viral genome comprising a nucleotide sequence encoding IGF-I or a functionally equivalent variant thereof which is operably linked to a liver-specific promoter.
A method for the treatment and/or prevention of hepatic cirrhosis or hepatic fibrosis comprising the administration to a subject in need thereof of a recombinant parvovirus comprising a sequence encoding IGF-I or a functionally equivalent variant thereof.
A method for preparing a recombinant AAV virion comprising the steps of
- (i) contacting a cell with
- (a) a first nucleic acid sequence comprising
- i. a expression cassette comprising a sequence encoding IGF-I or a functionally equivalent variant thereof which is operably linked to liver-specific promoter and
- ii. an AAV 5′-ITR and a 3′-ITR flanking the expression cassette defined in (i)
- (b) a second nucleic acid sequence encoding an AAV rep protein
- (c) a third nucleic acid sequence encoding an AAV cap protein and, optionally,
- (d) a fourth nucleic acid sequence encoding viral and/or cellular functions upon which AAV is dependent for replication
- under conditions adequate for entry of the three components in the cell and
- (ii) recovering the recombinant AAV virion from the cells.
Dependencies are inferred from the claim text.